Our Innovations
Here at Adelphi Real World, we always aim to maximise the real-world impact and reach of our scientific evidence and insights for patient and public benefit.
We communicate this via a collaborative energy between our research teams, our Scientific Advisory Board, and key stakeholders across the real world ecosystem.
When assessing the richness and depth of our real world data, key messages emerge such as new analytical techniques and approaches, highlighting advances in therapy areas and unmet needs in patient care.
We communicate this via a collaborative energy between our research teams, our Scientific Advisory Board, and key stakeholders across the real world ecosystem.
When assessing the richness and depth of our real world data, key messages emerge such as new analytical techniques and approaches, highlighting advances in therapy areas and unmet needs in patient care.
Our Innovations: The Adelphi Adherence Questionnaire (ADAQ©)
Whilst working with real world data across 100 therapy areas, and in consultation with external experts, we identified an unmet need in the market for assessing patient adherence.
We felt uniquely positioned to drive a robust adherence patient reported outcome measure (PROM) to share with industry:
Adelphi Real World are positioned at the forefront of real-world evidence generation involving physicians and patients
Our sister company Adelphi Values (Patient-Centered Outcomes) are experts in devising and validating PROMs
We have thousands of patients in-house from our proprietary Disease Specific ProgrammesTM on which to further psychometrically validate such a measure in a time efficient manner
Our existing relationships with external clinical experts ensured we had a robust approach
Our Innovations:
The Adelphi Adherence Questionnaire (ADAQ©)
– A validated patient adherence tool developed to FDA and clinical standards
We communicate this via a collaborative energy between our research teams, our Scientific Advisory Board, and key stakeholders across the real world ecosystem. When assessing the richness and depth of our real world data, key messages emerge such as new analytical techniques and approaches, highlighting advances in therapy areas and unmet needs in patient care.
The Adelphi Adherence Questionnaire (ADAQ©): Summary
The ADAQ© is a generic patient-reported medication adherence measure appropriate for use across different types of diseases and treatment modalities (injection, oral/tablet, topical), treatment schedules and adherence behaviours
Qualitative research has been conducted in line with best practice standards (FDA and EMA) to develop the ADAQ© items and confirm content validity. Psychometric validation was further assessed across Adelphi Disease Specific Programmes (DSPs)
ADAQ© has been developed and validated for pen & paper administration. The PRO can be administered electronically acknowledging this validation step has not been performed
14 validated languages available. Additional languages can be provided upon request
The Adelphi Adherence Questionnaire (ADAQ©) – A validated patient adherence tool developed to FDA and clinical standards
Adelphi Real World, in collaboration with our sister company Adelphi Values (Patient-Centered Outcomes) and three clinical experts, has developed the Adelphi Adherence Questionnaire (ADAQ©). The ADAQ© is a unique patient-reported outcome (PRO) assessment of medication adherence developed for use among a wide variety of chronic conditions and will be of immediate value to a variety of stakeholders including patients, clinicians, pharmaceutical and academic outcomes researchers, regulators, and payers.
ADAQ© followed best measurement development and evaluation standards equivalent to FDA guidance for disease-specific PRO measures. One aspect that sets ADAQ© apart from existing measures is the rigorous qualitative content validity testing with patients across a range of conditions (depression, schizophrenia, multiple sclerosis, hypertension, diabetes, psoriasis, asthma and multiple myeloma), treatment modalities (i.e. oral, inhaled, injectable) and countries and cultures.
The Adelphi Adherence Questionnaire (ADAQ©) – A validated patient adherence tool developed to FDA and clinical standards
Adelphi Real World, in collaboration with our sister company Adelphi Values (Patient-Centered Outcomes) and three clinical experts, has developed the Adelphi Adherence Questionnaire (ADAQ©). The ADAQ© is a unique patient-reported outcome (PRO) assessment of medication adherence developed for use among a wide variety of chronic conditions and will be of immediate value to a variety of stakeholders including patients, clinicians, pharmaceutical and academic outcomes researchers, regulators, and payers.
ADAQ© followed best measurement development and evaluation standards equivalent to FDA guidance for disease-specific PRO measures. One aspect that sets ADAQ© apart from existing measures is the rigorous qualitative content validity testing with patients across a range of conditions (depression, schizophrenia, multiple sclerosis, hypertension, diabetes, psoriasis, asthma and multiple myeloma), treatment modalities (i.e. oral, inhaled, injectable) and countries and cultures.
Guidance during the development of the ADAQ© was provided by clinicians with diverse disease adherence experience including Professor Kamlesh Khunti of the Diabetes Research Centre, Leicester University, UK, Professor Nicolas Roche of the Respiratory Medicine Department, Cochin Hospital – University Paris Cité, France and Dr. Rebecca Rossom of HealthPartners Institute (Mental Health, Aging and Chronic Disease), University of Minnesota Medical School, United States.
Following qualitative content validity testing, psychometric evaluation of the measure has also been extensive. Using data generated from 3,082 patients participating in a range of Adelphi Real World Disease Specific ProgrammesTM among patients presenting with atopic dermatitis, heart failure, HIV, multiple sclerosis, or osteoarthritis, results support the ADAQ© as capable of generating reliable and construct valid scores and useful real-world insights.
Adelphi Real World President Maria Karavali said: “We are excited that ADAQ© provides the medical community with a comprehensive, versatile, and simple adherence measure validated to the highest of standards across a variety of conditions and are enthusiastic about ADAQ© being applied in both real-world studies and routine clinical practice.”
Professor Khunti adds: “Medication adherence is both critical and instrumental for improving patient outcomes. I am delighted to have contributed to this widely applicable medication adherence measure which I hope will help identify people who have poor adherence with a view to implementing interventions to improve outcomes.”
Professor Roche further added: “As in most chronic conditions, adherence is problematic in chronic respiratory diseases, where many treatments are administered by inhalation using dedicated devices. A generic tool to measure adherence that has been tested in patients treated with such devices is an important progress in this field.”
We are excited that ADAQ© provides the medical community with a comprehensive, versatile, and simple adherence measure validated to the highest of standards
Highlighting the patient centric importance of ADAQ© in real-world clinical practice, Dr. Rebecca Rossom stated: “Too often we make assumptions about a patient’s medication adherence. The ADAQ© provides a systematic way of measuring general medication adherence and can serve as an important tool to understand how to best support our patients and improve their health.”
For further information, or to contract use of ADAQ©, please contact [email protected]
ADAQ© is fully owned by Adelphi Real World. ADAQ© validation publications (to date) for further information: Bentley S, Morgan L, Exall E, Arbuckle R, Rossom RC, Roche N, Khunti K, Higgins V, Piercy J. Qualitative Interviews to Support Development and Cognitive Debriefing of the Adelphi Adherence Questionnaire (ADAQ©): A Patient-Reported Measure of Medication Adherence Developed for Use in a Range of Diseases, Treatment Modalities, and Countries. Patient Prefer Adherence. 2022 Sep 15;16:2579-2592.
We communicate this via a collaborative energy between our research teams, our Scientific Advisory Board, and key stakeholders across the real world ecosystem.
When assessing the richness and depth of our real world data, key messages emerge such as new analytical techniques and approaches, highlighting advances in therapy areas and unmet needs in patient care.
We communicate this via a collaborative energy between our research teams, our Scientific Advisory Board, and key stakeholders across the real world ecosystem.
When assessing the richness and depth of our real world data, key messages emerge such as new analytical techniques and approaches, highlighting advances in therapy areas and unmet needs in patient care.
Please use the form below to search through our publications